RE: Resident Detectives17 Jan 2026 16:16
My opinion on HEMO in 2026
Vlad will want more from this. He is 12 years in, this is his life’s work, and he is constantly surrounded by people who have built and sold successful biotech companies. He also has a deep personal connection to HG CT-1 through his family, and genuinely wants this to succeed.
A partnership, JV, or acquisition would be the cleanest way to fund this with stability, but it still looks early relative to most CAR-T programmes. That said, across every CAR-T trial I’ve researched, Autolus included, the real inflection point tends to come once 10+ patients of data are generated. That is typically when multiple bidders emerge.
In CAR-T, dose escalation is widely recognised as the hardest phase, and AML makes it even tougher. Target overlap with healthy myeloid cells is the reason there are still no approved AML CAR-T therapies globally. Patient selection and clean safety data are everything at this stage. The question is simply, can Hemo be the first.
Until then, the priority is straightforward, secure solid funding on reasonable terms and get to those 10 patients.
HG CT-1 targets FLT3, one of the most validated targets in AML, and is positioned as a more complex and advanced CAR-T than what is currently in clinical development elsewhere. AML CAR-T is hard, but that is exactly why clean dose-escalation data would be so valuable. This is genuine innovation, not a copy-paste CAR-T model. If executed properly, it has the potential to scale into hundreds of millions in revenue within around 12 months of reaching that 10-patient milestone.
Right now, the most important thing is either securing a strong institutional deal, or consistently communicating real, verifiable progress, patient dosing, manufacturing readiness, and protocol milestones. A higher share price going into raises simply means less dilution, and a clearer path to getting those 10 patients done.
Sign In
Follow the stocks
